645 related articles for article (PubMed ID: 21497851)
1. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
Abdel-Meguid TA
J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
4. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.
Khan S; Game X; Kalsi V; Gonzales G; Panicker J; Elneil S; Apostolidis A; Hamid R; Dasgupta P; Kessler TM; Fowler CJ
J Urol; 2011 Apr; 185(4):1344-9. PubMed ID: 21334639
[TBL] [Abstract][Full Text] [Related]
7. [Injection of botulinum toxin (BTX-A) in children with bladder dysfunction due to detrusor overactivity].
Romero RM; Rivas S; Parente A; Fanjul M; Angulo JM
Actas Urol Esp; 2011 Feb; 35(2):89-92. PubMed ID: 21256633
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin treatment for bladder dysfunction.
Santos-Silva A; da Silva CM; Cruz F
Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions.
Bagi P; Biering-Sørensen F
Scand J Urol Nephrol; 2004; 38(6):495-8. PubMed ID: 15841785
[TBL] [Abstract][Full Text] [Related]
15. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
Kuo HC
Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
17. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X
J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679
[TBL] [Abstract][Full Text] [Related]
19. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
Kuo HC; Liao CH; Chung SD
Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses.
Grise P; Ruffion A; Denys P; Egon G; Chartier Kastler E
Eur Urol; 2010 Nov; 58(5):759-66. PubMed ID: 20674149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
